In addition to BACE1, our study utilizing multi-target drug modeling and surface plasmon resonance experiments identified Aβ 1-42 as a high-affinity target of berberine, suggesting its potential in treating Alzheimer’s disease (Chu et al., 2018). This evidence concerns the gene BACE1 and Alzheimer disease.